PTCT 241220 45.00C (PTCT241220C45000) Stock Options, News & Quotes

US OptionsDetailed Quotes

PTCT241220C45000

Watchlist

2.30
-1.40-37.84%

15min DelayClose Nov 27 16:00 ET

3.20High2.30Low

Intraday

5D
Daily

News

RBC Capital Remains a Hold on PTC Therapeutics (PTCT)
TipRanksNov 27 20:48 ET · Ratings
PTC Therapeutics ALS Drug Fails to Meet Endpoints as Trials Shut Down
Yahoo FinanceNov 27 10:12 ET
Baird Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $52
Moomoo NewsNov 27 08:31 ET · Ratings
Baird Maintains Outperform on PTC Therapeutics, Raises Price Target to $52
BenzingaNov 27 08:08 ET · Ratings
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
BenzingaNov 27 07:51 ET
TD Cowen Remains a Hold on PTC Therapeutics (PTCT)
TipRanksNov 27 07:35 ET · Ratings

Comments

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

mad541

May 20 07:38

$PTC Therapeutics (PTCT.US)$ just dud offering 22.87 a share get out 🔻🔻🔻🔻

Moomoo AI

Mar 3 08:56

PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.

There's No Escaping PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Muted Revenues Despite A 27% Share Price Rise

Moomoo AI

Feb 14 08:26

Recent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.

PTC Therapeutics Insiders Sold US$1.1m Of Shares Suggesting Hesitancy

Moomoo AI

Nov 18, 2023 08:43

PTC Therapeutics' ongoing losses may have led to negative market view, causing a contradictory movement in the stock against the company’s revenue growth. The firm's underperformance in the past five years suggests unresolved issues. Currently, the healthcare company has five investment analysis warning signs.

PTC Therapeutics (NASDAQ:PTCT) Adds US$145m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 68%